Oligometastatic Prostate Cancer Treatment Outcomes from Five Chinese Centers

Yujie Dong's multicenter retrospective study analyzes 160 oligometastatic prostate cancer patients treated between May 2010 and May 2023. It compares perioperative and oncological outcomes for patients receiving neoadjuvant hormonal therapy versus standard therapy, with a median follow-up of 52 months.

Use Cases

• Compare operative time and blood loss metrics between NHT and standard therapy groups for surgical outcome analysis
• Analyze pathological downstaging in T-stage and positive surgical margin rates as indicators of treatment efficacy
• Model biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) interactions with biopsy Gleason score ≥8
• Assess the incidence of ADT-related adverse events and subsequent treatment rates across patient cohorts

Strengths

• Data from 160 patients across five Chinese medical centers provides a multicenter perspective
• Study covers a 13-year time range from May 2010 to May 2023
• Includes multiple clinical endpoints: bPFS, rPFS, OS, and perioperative metrics

Limitations

• Small sample size of 160 total patients limits statistical power for subgroup analyses
• Retrospective study design may introduce selection bias and confounding factors
• Data is presented in a DOCX document (15.9 KB), not a structured tabular format for direct analysis

Provenance

Source

Yujie Dong via figshare

Collection Method

Multicenter retrospective study

Time Range

May 2010 to May 2023

Freshness

Data collection ended May 2023; document last updated March 2026.

Geography

Five medical centers in China